Global and regional immunization profile

Data received as of 2019-Jul-01

Global

Next overall update Winter 2019
Next WHO UNICEF estimates July 2020

Population data in thousands [1]

	2018	2017	2016	2015	2014	2000	1990	1980
Total population	7'586'693	7'503'627	7'419'957	7'335'912	7'251'601	6'103'694	5'291'866	4'427'669
Live births	139'677	139'720	139'699	139'607	139'443	131'627	136'960	124'049
Surviving infants	135'636	135'573	135'439	135'225	134'928	124'596	128'050	114'079
Pop. less than 5 years	673'691	672'136	670'287	668'106	665'621	612'607	640'465	544'300
Pop. less than 15 years	1'957'802	1'946'819	1'935'296	1'923'606	1'912'530	1'841'852	1'738'265	1'565'261
Female 15-49 years	3'857'865	3'833'387	3'807'947	3'781'175	3'753'436	3'184'629	2'672'449	2'148'438

Number of reported cases

Diphtheria	16'648	8'819	7'101	4'535	7'774	11'625	23'864	97'511
Japanese encephalitis	4'402	4'668	5'399	4'086	4'810	-	-	-
Measles	353'236	173'457	132'413	214'816	282'078	853'479	1'374'083	4'211'431
Mumps	499'037	560'622	591'684	385'736	311'599	544'093	-	-
Pertussis	151'074	162'938	174'177	149'089	177'083	190'475	476'374	1'982'355
Polio	104	96	42	106	415	2'971	23'390	52'795
Rubella	26'006	16'393	23'418	23'760	33'514	670'894	-	-
Rubella (CRS)	449	835	369	282	142	156	-	-
Tetanus (neonatal)	1'803	2'266	1'997	3'580	2'238	17'935	25'293	13'005
Tetanus (total)	15'103	12'509	13'813	10'337	12'531	23'711	64'983	114'251
Yellow fever	2'064	876	1'154	72	54	699	4'339	144

Percentage of target population vaccinated, by antigen

based on WHO-UNICEF estimates
TT2plus is based on reported coverage

BCG	89	89	89	88	88	80	81	15
DTP1	90	91	91	90	89	83	88	30
DTP3	86	86	86	85	84	72	75	20
HepB_BD	42	41	37	37	35	5	-	-
HepB3	84	84	85	83	81	30	1	-
Hib3	72	72	71	63	55	13	0	-
IPV1	72	58	47	23	-	-	-	-
MCV1	86	86	86	85	84	72	73	16
MCV2	69	68	67	63	59	18	-	-
PCV3	47	45	43	38	32	-	-	-
Pol3	85	86	85	85	85	73	75	21
RCV1	69	52	48	47	45	21	8	3
rotac	35	28	25	23	19	-	-	-
TT2plus	72	73	72	70	67	62	55	9
YFV	49	48	46	42	43	11	-	-

Most countries have standard recommendations regarding which vaccines should be offered and at what ages they should be given. In general, vaccines are recommend for the youngest age group at risk for developing the disease whose members are known to respond to the immunization without adverse effects.

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).
IPV global and regional coverage calculation is for 144 bOPV using countries.

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.

1) "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.